Treatment of high risk Sertoli-Leydig cell tumors of the ovary using a gonadotropin releasing hormone (GnRH) analog

Pediatric Blood and Cancer

Volumn 60, Issue 6, 2013, Pages

  Lashkari, Harsha Prasada ^a   Nash, Ruth ^b   Albanese, Assunta ^a,b   Okoye, Bruce ^a,b   Millar, Robert ^c,d,e   Pritchard Jones, Kathy ^f  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF PRETORIA   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

GnRH analog; Leuprorelin; Sertoli Leydig cell tumor (SLCT); Sex cord stromal cell tumor

Indexed keywords

ALPHA FETOPROTEIN; CARBOPLATIN; DICER; ESTRADIOL; ETOPOSIDE; FOLLITROPIN; GONADOTROPIN; GONADOTROPIN RECEPTOR; INHIBIN A; INHIBIN B; LEUPRORELIN; LUTEINIZING HORMONE; MELPHALAN;

ABDOMINAL DISTENSION; ABDOMINAL MASS; ANDROBLASTOMA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CASE REPORT; CHILD; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DICER1 GENE; DRUG EFFICACY; ESTROGEN THERAPY; FEMALE; GENE; GENE MUTATION; GENETIC PREDISPOSITION; GYNECOLOGIC SURGERY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEYDIG CELL; LYMPH NODE METASTASIS; MENORRHAGIA; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; SCHOOL CHILD; SERTOLI CELL; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS, HORMONAL; CHILD; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUPROLIDE; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; SERTOLI-LEYDIG CELL TUMOR;

EID: 84876437926     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24382     Document Type: Article

References (17)

1. Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 1985; 9: 543-569.
2. Colombo N, Parma G, Zanagnolo V, et al. Management of ovarian stromal cell tumors. J Clin Oncol 2007; 25: 2944-2951.
3. Schneider DT, Janig U, Calaminus G, et al. Ovarian sex cord-stromal tumors-A clinicopathological study of 72 cases from the Kiel Pediatric Tumor Registry. Virchows Arch 2003; 443: 549-560.
4. Schneider DT, Calaminus G, Wessalowski R, et al. Ovarian sex cord-stromal tumors in children and adolescents. J Clin Oncol 2003; 21: 2357-2363.
5. Gobel U, Schneider DT, Calaminus G, et al. Germ-cell tumors in childhood and adolescence. GPOH MAKEI and the MAHO study groups. Ann Oncol 2000; 11: 263-271.
6. Millar RP, Garritsen A, Hazum E. Characterization of Leydig cell gonadotropin-releasing hormone binding sites utilizing radiolabeled agonist and antagonist. Peptides 1982; 3: 789-792.
7. Stadel BV. Letter: The etiology and prevention of ovarian cancer. Am J Obstet Gynecol 1975; 123: 772-774.
8. Davy M, Torjesen PA, Aakavaag A. Demonstration of an FSH receptor in a functioning granulosa cell tumour. The effect of gonadotrophin treatment on its viability following transplantation to nude mice. Acta Endocrinol (Copenh) 1977; 85: 615-623.
9. Fishman A, Kudelka AP, Tresukosol D, et al. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. J Reprod Med 1996; 41: 393-396.
10. Emons G, Schally AV. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod 1994; 9: 1364-1379.
11. Gnanapragasam VJ, Darby S, Khan MM, et al. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer. J Pathol 2005; 206: 205-213.
12. Millar R. Recent data on GnRH receptors. Ann Urol (Paris) 2005; 39: 32-36.
13. Waxman J. Gonadotrophin hormone releasing analogues open new doors in cancer treatment. Br Med J (Clin Res Ed) 1987; 295: 1084-1085.
14. Grundker C, Emons G. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol 2003; 1: 65.
15. White CD, Stewart AJ, Lu ZL, et al. Antiproliferative effects of GnRH agonists: Prospects and problems for cancer therapy. Neuroendocrinology 2008; 88: 67-79.
16. Chao HT, Wang PH, Lin HD. Gonadotropin-releasing hormone-agonist as a neoadjuvant therapy for Sertoli-Leydig cell tumors of the ovary. Int J Gynaecol Obstet 1999; 66: 189-190.
17. Slade I, Bacchelli C, Davies H, et al. DICER1 syndrome: Clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J Med Genet 2011; 48: 273-278.